Vivasure Medical, Ltd. appears in FDA device records as the applicant behind a single premarket approval in the retrieved collection: P250015 for the PerQseal® Elite Vascular Closure Device, decided 16 October 2026. The filing lists a Galway, Ireland address and the cardiovascular advisory committee. That record is the anchor for distinguishing the regulated applicant from the product brand and from any corporate parent, and it defines the documented scope of the device rather than its commercial reach. [1][2]

The FDA applicant and its approval record

P250015 was received on 16 June 2025 and approved on 16 October 2026 under product code MGB, generic name Device, hemostasis, vascular, device class 3. The applicant of record is Vivasure Medical, Ltd.; the trade name is PerQseal® Elite Vascular Closure Device. The record carries no expedited review flag and no supplement number, so it reads as an original approval rather than a supplement to an earlier filing. [1]

The retrieved collection holds one linked premarket approval record, and its decision count is one approval. The smaller record sample likewise contains that single approval, so the two counts describe the same filing at different levels of detail and neither supports any statement about the company’s total portfolio, sales or safety history. [1][2]

Documented device and components

The approved indication covers percutaneous closure of common femoral arteriotomies after interventional endovascular catheterization procedures using 14–22 F sheaths, with arteriotomies up to 26 F. Vivasure’s own materials describe PerQseal® Elite as a 100% bio-absorbable, sutureless patch-based closure system for arterial and venous access, and the brochure repeats the 14–22 F sheath range with arteriotomy up to 26 F. [1][3][9]

The device is documented as two packaged parts. The PerQseal® Elite Closure Device sits in a thermoformed tray inside a Tyvek pouch, which is itself inside a non-sterile foil moisture barrier; the Tyvek pouches form the sterile barrier system. A separate PerQseal® Elite Introducer is described as a single-use, disposable, radiopaque catheter that provides a flexible conduit for access to the femoral vasculature. [7][8][9]

The instructions for use state that the device should be used only by physicians who have completed Vivasure-approved training, and the introducer instructions carry the same manufacturer address in Galway, Ireland. Catalogue number DP4-P1-2-G is listed as containing the closure device with the introducer sheath. [5][8][9]

Regulatory status across markets

Vivasure’s website states that PerQseal® Elite is CE mark approved and not available for sale in the United States, and the brochure repeats the CE mark statement for both the closure device and the introducer. The same page identifies the company as part of Haemonetics, a statement published by Vivasure rather than by FDA. [3][6][9]

The European documentation references a Basic UDI-DI, 539153318DP4FA1VCDV7, for lookup in the Eudamed database when available. The FDA approval and the CE mark statements come from different publishers and describe different regulatory pathways; neither record establishes launch timing, pricing or hospital adoption. [1][9]

What the record does not establish

The FDA filing address in Galway is a correspondence address on a regulatory record and is not presented here as a corporate headquarters. Ownership beyond the Haemonetics statement on Vivasure’s site, manufacturing sites, distribution partners and customer relationships are not documented in the retrieved sources. [1][6]

Clinical performance figures appear in Vivasure’s brochure as references to data on file, without results in the retrieved text, so no efficacy or safety outcome is reported here. The retrieved collection contains no recall records for this applicant, which is an absence in the retrieved data rather than a finding about device performance. [1][9]